Disrupting glioblastoma networks with tumor treating fields (TTFields) in in vitro models

被引:1
|
作者
Schlieper-Scherf, Steffen [1 ]
Hebach, Nils [2 ,3 ,4 ]
Hausmann, David [2 ,3 ,4 ]
Azorin, Daniel D. [2 ,3 ,4 ]
Hoffmann, Dirk C. [2 ,3 ,4 ]
Horschitz, Sandra [5 ,6 ]
Maier, Elena [1 ]
Koch, Phillip [5 ,6 ]
Karreman, Matthia A. [2 ,3 ,4 ]
Etminan, Nima [1 ]
Ratliff, Miriam [1 ,2 ]
机构
[1] Heidelberg Univ, Univ Hosp Mannheim, Dept Neurosurg, Mannheim, Germany
[2] German Canc Consortium DKTK, German Canc Res Ctr DKFZ, Clin Cooperat Unit Neurooncol, Heidelberg, Germany
[3] Univ Hosp Heidelberg, Neurol Clin, Heidelberg, Germany
[4] Univ Hosp Heidelberg, Natl Ctr Tumor Dis, Heidelberg, Germany
[5] Heidelberg Univ, Cent Inst Mental Hlth, Med Fac Mannheim, Mannheim, Germany
[6] Hector Inst Translat Brain Res HITBR gGmbH, Mannheim, Germany
关键词
Glioma; Cancer neuroscience; Tumor microtubes; Cancer cell network; TTFields; ELECTRIC-FIELD; CELLS; RADIOTHERAPY; CANCER;
D O I
10.1007/s11060-024-04786-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeThis study investigates the biological effect of Tumor Treating Fields (TTFields) on key drivers of glioblastoma's malignancy-tumor microtube (TM) formation-and on the function and overall integrity of the tumor cell network.MethodUsing a two-dimensional monoculture GB cell network model (2DTM) of primary glioblastoma cell (GBC) cultures (S24, BG5 or T269), we evaluated the effects of TTFields on cell density, interconnectivity and structural integrity of the tumor network. We also analyzed calcium (Ca2+) transient dynamics and network morphology, validating findings in patient-derived tumoroids and brain tumor organoids.ResultsIn the 2DTM assay, TTFields reduced cell density by 85-88% and disrupted network interconnectivity, particularly in cells with multiple TMs. A "crooked TM" phenotype emerged in 5-6% of treated cells, rarely seen in controls. Ca2+ transients were significantly compromised, with global Ca2+ activity reduced by 51-83%, active and periodic cells by over 50%, and intercellular co-activity by 52% in S24, and almost completely in BG5 GBCs. The effects were more pronounced at 200 kHz compared to a 50 kHz TTFields. Similar reductions in Ca2+ activity were observed in patient-derived tumoroids. In brain tumor organoids, TTFields significantly reduced tumor cell proliferation and infiltration.ConclusionOur comprehensive study provides new insights into the multiple effects of Inovitro-modeled TTFields on glioma progression, morphology and network dynamics in vitro. Future in vivo studies to verify our in vitro findings may provide the basis for a deeper understanding and optimization of TTFields as a therapeutic modality in the treatment of GB.
引用
收藏
页码:139 / 151
页数:13
相关论文
共 50 条
  • [21] The safety profile of Tumor Treating Fields (TTFields) therapy in glioblastoma patients with ventriculoperitoneal shunts
    Oberheim-Bush, Nancy Ann
    Shi, Wenyin
    McDermott, Michael W.
    Grote, Alexander
    Stindl, Julia
    Lustgarten, Leonardo
    JOURNAL OF NEURO-ONCOLOGY, 2022, 158 (03) : 453 - 461
  • [22] Tumor Treating Fields (TTFields) Therapy and Lomustine Chemotherapy for the Treatment of Unresectable Progressive Glioblastoma
    Mergen, Ertan
    Landrock, Sonja
    Chizzali, Barbara
    CASE REPORTS IN ONCOLOGY, 2024, 17 (01): : 1056 - 1062
  • [23] Association of tumor treating fields (TTFields) therapy with overall survival in newly diagnosed glioblastoma
    Shah, Siddharth
    Nag, Aiswarya
    Lucke-Wold, Brandon
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025,
  • [24] Concurrent Tumor Treating Fields (TTFields) and dexamethasone decrease proliferation and clonogenicity of patient-derived glioblastoma cells in vitro
    Michelhaugh, Sharon K.
    Kiousis, Sam
    Mittal, Sandeep
    CANCER RESEARCH, 2019, 79 (13)
  • [25] Inhibition of AURKA destabilizes glioblastoma primary cilia and sensitizes cells to tumor treating fields (TTFields) in vitro and ex vivo
    Tian, Jia
    Mallinger, Julianne
    Shi, Ping
    Ling, Dahao
    Deleyrolle, Loic
    Lin, Min
    Khoshbouei, Habibeh
    Sarkisian, Matthew
    CANCER RESEARCH, 2023, 83 (07)
  • [26] IDH1-MUTANT GLIOBLASTOMA (GBM) CELLS FROM A PATIENT POST-TUMOR TREATING FIELDS (TTFIELDS) THERAPY ARE SENSITIVE TO TTFIELDS IN VITRO
    Michelhaugh, Sharon
    Kiousis, Sam
    Klinger, Neil
    Mittal, Sandeep
    NEURO-ONCOLOGY, 2018, 20 : 223 - 223
  • [27] ENHANCED THERAPEUTIC BENEFITS OF TUMOR TREATING FIELDS (TTFIELDs) ON SUPERFICIALLY LOCATED GLIOBLASTOMA MULTIFORME (GBM)
    Harris, David
    Kumar, Vaibhav
    Mehan, William
    Madan, Neel
    Moreno-Koehler, Alejandro
    Linendoll, Nadine
    Saif, Nawal
    Quinkert, Amy
    Mignano, John
    Wu, Julian
    Jeyapalan, Suriya
    NEURO-ONCOLOGY, 2016, 18 : 180 - 180
  • [28] HISTOPATHOLOGICAL AND GENOMIC CHARACTERIZATION OF GLIOBLASTOMA (GBM) RESECTED AFTER TUMOR TREATING FIELDS (TTFIELDS) THERAPY
    Michelhaugh, Sharon
    Kiousis, Sam
    Mittal, Sandeep
    NEURO-ONCOLOGY, 2018, 20 : 223 - 223
  • [29] Tumor-treating fields (TTFields)-based cocktail therapy: a novel blueprint for glioblastoma treatment
    Wang, Minjie
    Zhang, Chaocai
    Wang, Xuan
    Yu, Hao
    Zhang, Hemei
    Xu, Junnv
    Zhao, Jiannong
    Jiang, Xiaobing
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (04): : 1069 - 1086
  • [30] Tumor-treating fields (TTFields) effects on glioblastoma cells are augmented by mitotic checkpoint inhibition
    Kessler, Almuth F.
    Froembling, Greta E.
    Gross, Franziska
    Hahn, Mirja
    Dzokou, Wilfrid
    Ernestus, Ralf-Ingo
    Loehr, Mario
    Hagemann, Carsten
    CANCER RESEARCH, 2018, 78 (13)